What are research peptides?

Research peptides are synthetic peptides, that is, short chains of amino acids made in the laboratory, intended for laboratory and analytical research. They carry the label "Research Use Only" (RUO). They have no marketing authorisation as medicines and are not sold as food supplements or cosmetics. They are not intended for use in humans or animals.

The term does not describe a group of molecules with a shared chemistry. It describes the intended purpose of a material. The same peptide can exist as research material in a laboratory and, through an entirely different route of production, testing and authorisation, as a medicine. The category is defined by intended purpose, manufacturing and regulatory framework, not by the amino-acid sequence.

This text is a guide to the category: what the RUO label means, how a research peptide differs from a medicine and from a supplement, which research categories exist, what has been studied in humans and how a batch is documented. For what peptides are in general, see the guide "What are peptides".

The RUO label comes from the regulatory framework for in vitro diagnostic products. In the United States, regulation 21 CFR 809.10(c)(2)(i) provides that a diagnostic product in the laboratory research phase, not represented as an effective diagnostic product, carries the statement "For Research Use Only. Not for use in diagnostic procedures." Today the label is used more broadly for reagents, reference standards and other materials intended for laboratories. The provision concerns diagnostic products; on its own it does not set a status for peptides.

In practice, the RUO label states three things:

• The intended purpose of the material is laboratory research, for example cell-culture experiments, biochemical analyses, development of analytical methods or use as a reference standard.
• The material has not gone through the process required for a medicine or for any product intended for humans or animals.
• The material comes with no indications, instructions or claims for use in humans or animals.

The RUO label is not a quality certificate. On its own it says nothing about the identity or purity of the material. These are documented separately, with analyses per batch, as described below.

In the European Union, Directive 2001/83/EC (Article 1, point 2) defines a medicinal product as any substance presented as having properties for treating or preventing disease in human beings, as well as any substance that may be used in or administered to human beings in order to restore, correct or modify physiological functions by exerting a pharmacological, immunological or metabolic action, or to make a medical diagnosis. A medicine is placed on the market only after it receives a marketing authorisation, from the European Commission, on the recommendation of the European Medicines Agency (EMA), or from the national authority, which in Greece is the EOF.

Before a marketing authorisation is granted, years of studies come first: preclinical studies in cells and animals and, after that, clinical studies in humans in successive phases. Manufacturing follows good manufacturing practice (GMP) rules, and the medicine comes with a summary of product characteristics and a package leaflet. After it reaches the market, the authorities monitor adverse reactions.

A research peptide has none of these. It has no marketing authorisation as a medicine, no indications and no package leaflet. For many research peptides, clinical studies in humans have not been completed. The difference is not a formality. It is the difference between a substance whose action and risks in humans have been studied systematically and a substance for which this has not been done.

The word "peptides" appears on four very different kinds of product, governed by different rules:

• Medicine: requires a marketing authorisation, clinical studies in humans, indications and a package leaflet (Directive 2001/83/EC).
• Food supplement: is a food intended to supplement the normal diet (Directive 2002/46/EC), and its health claims are controlled under Regulation 1924/2006.
• Cosmetic: is a substance or mixture intended to be placed in contact with external parts of the body (for example the skin, hair or nails) in order to clean, perfume, protect or change the appearance of them, or keep them in good condition (Regulation 1223/2009).
• Research peptide: is a material for the laboratory, with no indications and no instructions, and is not intended for humans or animals.

The best-known example of "peptides" in supplements is collagen peptides: collagen of animal origin broken down into small pieces. It is a mixture of many different peptides, not one specific molecule. A research peptide, by contrast, is one specific amino-acid sequence, chemically synthesised.

The distinction is clear in GHK-Cu, the copper peptide: as an ingredient of a skin serum it is a cosmetic, while as a powder for laboratory use it is research material. The molecule is the same; the category, the rules and the data that apply to each form are different.

Research peptides are usually classified by the biological field in which they are studied. The classification is bibliographic: it shows where research focuses, not any result. Below are the main categories, with a short description and a link to the monograph on each substance. The list is not complete; it includes the substances for which there is a monograph on this blog.

• Tissue biology. BPC-157 is a synthetic peptide of 15 amino acids with the sequence GEPPPGKPADDAGLV (Cox et al., Drug Test Anal 2017, PMID 28035768). It is studied mainly in animal models of tendon, muscle and gastrointestinal injury. Thymosin beta-4 and TB-500 are two different molecules: thymosin beta-4 is a protein present in almost all cells, while TB-500 is a small synthetic fragment of it.
• Skin and extracellular matrix. GHK-Cu is a tripeptide (glycine, histidine, lysine) that binds copper ions. It is studied in fibroblast cultures in relation to collagen synthesis.
• Mitochondrial peptides. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It was described in 2015, in a study in cells and mice (Lee et al., Cell Metab 2015, PMID 25738459), and is studied in relation to cellular metabolism and skeletal muscle.
• Redox balance. Glutathione is a tripeptide (glutamic acid, cysteine, glycine) made inside cells that takes part in enzymatic redox reactions. In research it is often used as a marker of the redox state of cells.
• Neuropeptides. Selank is a synthetic analogue of the peptide tuftsin (Kolomin et al., Regul Pept 2011, PMID 21609736). DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, isolated from rabbits; in the 1977 study, its synthetic form was tested in 58 rabbits (Schoenenberger and Monnier, PNAS 1977, PMID 265572).
• Metabolic signalling. Peptides studied in relation to the signalling of gut-hormone receptors. Some substances in this category are also marketed as medicines with a marketing authorisation, which is why they are not presented in detail here.

For most substances on the list, the data come mainly from cells and animals. Data in humans are few, small and of a different type for each substance. A comparison group and randomisation are what allow a result to be attributed to the substance rather than to other factors. A case series or a retrospective chart review shows what was observed, not what caused it.

By way of example, what has been published, by substance (the full picture is in the monographs):

• BPC-157: a retrospective chart review with telephone follow-up of 16 patients with knee pain (Lee and Padgett, Altern Ther Health Med 2021, PMID 34324435) and a pilot study in 12 women with interstitial cystitis (Lee et al., Altern Ther Health Med 2024, PMID 39325560) were published. Both were carried out in private clinics and neither had a comparison group.
• Thymosin beta-4: in a small randomised, controlled phase 2 trial, 9 patients with severe dry eye received thymosin beta-4 eye drops or a control preparation (Sosne et al., Cornea 2015, PMID 25826322). For TB-500 itself, a PubMed search on 26/10/2026 (terms: TB-500 or TB500) found no controlled clinical study in humans.
• GHK-Cu: in a randomised trial, 13 participants completed a programme with skin-care products with or without GHK-Cu, after ablative CO2 laser resurfacing. Objective measurements showed no difference between groups; in the questionnaire, the GHK-Cu group rated the improvement in overall skin quality higher (P = 0.04) (Miller et al., Arch Facial Plast Surg 2006, PMID 16847171).
• MOTS-c: in humans, the levels the body produces itself have been measured. In a 2021 study, exercise was associated with increased MOTS-c expression in skeletal muscle and in the circulation (Reynolds et al., Nat Commun 2021, PMID 33473109). The administration experiments in the same study were done in mice.
• Selank: a comparative study in 60 patients with phobic-anxiety and somatoform disorders was published, in Russian (Medvedev et al., Zh Nevrol Psikhiatr Im S S Korsakova 2014, PMID 25176261). Many of the publications on Selank come from institutes of the Russian Academy of Sciences.
• DSIP: the original experiments were done in rabbits (PMID 265572), and its biological role in humans remains open (see "What we do not know").

Each batch (or lot) of a research peptide is one specific production run. Its documentation answers two questions: whether the molecule is the one stated on the label (identity) and how much of the material is actually that molecule (purity). Two basic analytical methods:

• HPLC (high-performance liquid chromatography): separates the components of the sample and measures purity as a percentage.
• MS (mass spectrometry): measures the molecular mass and confirms that it matches the expected peptide.

The results are recorded in the certificate of analysis (COA). A COA usually states the substance, the batch number, the purity by HPLC, the MS result, the date of the analysis and the laboratory that ran it. Three points matter when reading it:

• The COA concerns one batch. It applies to material with the same batch number and not to other production runs. The match is made through the batch number, which appears both on the COA and on the label.
• An analysis by an independent laboratory carries different weight from an analysis by the manufacturer itself.
• A COA documents identity and purity. It does not certify suitability for use in humans or animals.

Why documentation matters is shown by published analyses of peptide preparations outside a controlled supply chain. Of 36 seized samples examined in 2019 at a forensic chemistry laboratory in Denmark, 9 contained no peptide or protein at all (Høj et al., Drug Test Anal 2021, PMID 33686802). In a systematic analysis of falsified peptide medicines from three suspect online pharmacies in Belgium, the purity of cysteine-containing peptides ranged from 5% to 75%, and arsenic and lead were found in samples (Janvier et al., Talanta 2018, PMID 30029448). In an analysis of products sold online under the name TB500, the content was not consistently in line with their description (Delcourt et al., Drug Test Anal 2022, PMID 36482504).

Published certificates are in the COA library.

• Research in humans is at an early stage for most substances on the list. The studies are small and often have no comparison group.
• Findings in cells and animals show where research is worth pursuing. They do not show what happens in humans.
• For most substances there are no long-term follow-up data in humans.
• For some substances, much of the literature comes from a few research groups, and independent replications are few.
• For some molecules the biological role remains open. For DSIP, a 2006 review noted that its link with sleep was never further characterised, in part because its gene, precursor protein and possible receptor have not been isolated (Kovalzon and Strekalova, J Neurochem 2006, PMID 16539679).
• The same name does not always correspond to the same molecule, as with thymosin beta-4 and TB-500. The findings of one study do not necessarily concern a material with a similar name.
• The regulatory status of some substances in the United States is in a transitional stage, and final decisions are pending.

No. They have no marketing authorisation as medicines, no indications and no package leaflet, and they are not intended for humans or animals.

No. Food supplements are foods intended for consumption. Research peptides are materials for laboratory research.

Research Use Only. It states the intended purpose of the material, not its quality.

Because the category is defined by intended purpose, manufacturing, testing and marketing authorisation, not by the chemical structure of the molecule.

For a few substances, and they are small. Most data come from cells and animals, and for some substances there are no controlled studies in humans.

The identity and purity of one specific batch, as measured with analytical methods such as HPLC and mass spectrometry. It does not certify suitability for use in humans or animals.

• Cox HD et al. Drug Test Anal. 2017. PMID 28035768 · DOI 10.1002/dta.2152
• Lee C et al. Cell Metab. 2015. PMID 25738459 · DOI 10.1016/j.cmet.2015.02.009
• Kolomin T et al. Regul Pept. 2011. PMID 21609736 · DOI 10.1016/j.regpep.2011.05.001
• Schoenenberger GA, Monnier M. Proc Natl Acad Sci U S A. 1977. PMID 265572 · DOI 10.1073/pnas.74.3.1282
• Lee E, Padgett B. Altern Ther Health Med. 2021. PMID 34324435
• Lee E et al. Altern Ther Health Med. 2024. PMID 39325560
• Sosne G et al. Cornea. 2015. PMID 25826322 · DOI 10.1097/ICO.0000000000000379
• Miller TR et al. Arch Facial Plast Surg. 2006. PMID 16847171 · DOI 10.1001/archfaci.8.4.252
• Reynolds JC et al. Nat Commun. 2021. PMID 33473109 · DOI 10.1038/s41467-020-20790-0
• Medvedev VE et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PMID 25176261
• Høj LJ et al. Drug Test Anal. 2021. PMID 33686802 · DOI 10.1002/dta.3026
• Janvier S et al. Talanta. 2018. PMID 30029448 · DOI 10.1016/j.talanta.2018.06.023
• Delcourt V et al. Drug Test Anal. 2022. PMID 36482504 · DOI 10.1002/dta.3421
• Kovalzon VM, Strekalova TV. J Neurochem. 2006. PMID 16539679 · DOI 10.1111/j.1471-4159.2006.03693.x
• 21 CFR 809.10(c)(2)(i), US Code of Federal Regulations
• Directive 2001/83/EC · Directive 2002/46/EC · Regulation (EC) 1924/2006 · Regulation (EC) 1223/2009

An informational text summarising published research. It is not medical advice or usage guidance.